Clinical Trial Update: ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ATRA and SDK002 in combination with chemotherapy and an anti-PD-1 inhibitor for advanced pancreatic ductal adenocarcinoma. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• ATRA (all-trans retinoic acid)
• SDK002

Snippet

Sponsor: Daniel Breadner | Conditions: Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: NOT_YET_RECRUITING